Press Releases

Date	Title	PDF Version
Jun 02, 2015	Alexion to Present at Investor Conferences
May 29, 2015	Alexion and Synageva Announce Early Termination of Hart-Scott-Rodino Waiting Period for Alexion's Pending Acquisition of Synageva
May 06, 2015	Alexion to Acquire Synageva to Strengthen Global Leadership in Developing and Commercializing Transformative Therapies for Patients with Devastating and Rare Diseases
May 05, 2015	Researchers Present New Data from Phase 2 Clinical Trial of Eculizumab (Soliris®) in Prevention of Acute Antibody-Mediated Rejection (AMR) in Sensitized Deceased-Donor Kidney Transplant Recipients
Apr 29, 2015	Alexion to Present at Investor Conferences
Apr 23, 2015	Alexion Reports First Quarter 2015 Results
Apr 13, 2015	Alexion Announces Presentations at 2015 American Transplant Congress, Including Results from Studies Advancing the Understanding of Eculizumab (Soliris®) in Patients Undergoing Kidney Transplant
Apr 09, 2015	Alexion Pharmaceuticals to Report First Quarter 2015 Results on Thursday, April 23, 2015
Mar 07, 2015	New Data from First Natural History Study in Juveniles with Hypophosphatasia (HPP) Showing Substantial Disease Burden, Including Musculoskeletal Abnormalities and Growth Deficiencies, Presented in Late-Breaking Oral Session at ENDO 2015
Mar 02, 2015	FDA Grants Priority Review for Asfotase Alfa as a Treatment for Patients with Hypophosphatasia

Search